Literature DB >> 22298988

Therapeutic vaccines for gastrointestinal cancers.

Osama E Rahma, Samir N Khleif.   

Abstract

Despite progress in the management of gastrointestinal malignancies, these diseases remain devastating maladies. Conventional treatment with chemotherapy and radiation is still only partially effective and highly toxic. In the era of increasing knowledge of the molecular biology of tumors and the interaction between the tumor and immune system, the development of targeted agents, including cancer vaccines, has emerged as a promising modality. In this paper, we discuss the principals of vaccine development, and we review most of the published trials on gastrointestinal cancer vaccines that have been conducted over the last decade. Many antigens and various treatment approaches have already been tested in colon, pancreatic, and other cancers. Some of these approaches have already shown some clinical benefit. In this paper, we discuss these different strategies and some of the future directions for targeting gastrointestinal malignancies with vaccines.

Entities:  

Keywords:  Cancer vaccine; gastrointestinal; malignancies; review; trials

Year:  2011        PMID: 22298988      PMCID: PMC3264936     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN: 1554-7914


  107 in total

Review 1.  Ras/Raf signalling and emerging pharmacotherapeutic targets.

Authors:  Walter Kolch
Journal:  Expert Opin Pharmacother       Date:  2002-06       Impact factor: 3.889

Review 2.  Immunotherapy of hepatocellular carcinoma.

Authors:  Firouzeh Korangy; Bastian Höchst; Michael P Manns; Tim F Greten
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2010-06       Impact factor: 3.869

3.  Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.

Authors:  Sjoerd H van der Burg; Anand G Menon; Anke Redeker; Marie-Claude Bonnet; Jan Wouter Drijfhout; Rob A E M Tollenaar; Cornelis J H van de Velde; Philippe Moingeon; Peter J K Kuppen; Rienk Offringa; Cornelis J M Melief
Journal:  Clin Cancer Res       Date:  2002-05       Impact factor: 12.531

4.  Adjuvant active specific immunotherapy of stage II and stage III colon cancer with an autologous tumor cell vaccine: first randomized phase III trials show promise.

Authors:  M G Hanna; H C Hoover; J B Vermorken; J E Harris; H M Pinedo
Journal:  Vaccine       Date:  2001-03-21       Impact factor: 3.641

5.  Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer.

Authors:  B T Brett; S C Smith; C V Bouvier; D Michaeli; D Hochhauser; B R Davidson; T R Kurzawinski; A F Watkinson; N Van Someren; R E Pounder; M E Caplin
Journal:  J Clin Oncol       Date:  2002-10-15       Impact factor: 44.544

6.  Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests.

Authors:  W J Lesterhuis; I J M de Vries; D H Schuurhuis; A C I Boullart; J F M Jacobs; A J de Boer; N M Scharenborg; H M H Brouwer; M W M M van de Rakt; C G Figdor; T J Ruers; G J Adema; C J A Punt
Journal:  Ann Oncol       Date:  2006-04-06       Impact factor: 32.976

Review 7.  Immune infiltration in human cancer: prognostic significance and disease control.

Authors:  Wolf H Fridman; Jérome Galon; Marie-Caroline Dieu-Nosjean; Isabelle Cremer; Sylvain Fisson; Diane Damotte; Franck Pagès; Eric Tartour; Catherine Sautès-Fridman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

Review 8.  Mucins and mucin binding proteins in colorectal cancer.

Authors:  James C Byrd; Robert S Bresalier
Journal:  Cancer Metastasis Rev       Date:  2004 Jan-Jun       Impact factor: 9.264

Review 9.  Cancer vaccination with telomerase peptide GV1001.

Authors:  Jon Amund Kyte
Journal:  Expert Opin Investig Drugs       Date:  2009-05       Impact factor: 6.206

10.  Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination.

Authors:  Hisashi Wada; Eiichi Sato; Akiko Uenaka; Midori Isobe; Ryohei Kawabata; Yurika Nakamura; Shigemichi Iwae; Kouichiro Yonezawa; Makoto Yamasaki; Hiroshi Miyata; Yuichiro Doki; Hiroshi Shiku; Achim A Jungbluth; Gerd Ritter; Roger Murphy; Eric W Hoffman; Lloyd J Old; Morito Monden; Eiichi Nakayama
Journal:  Int J Cancer       Date:  2008-11-15       Impact factor: 7.396

View more
  5 in total

Review 1.  Pancreatic cancer, treatment options, and GI-4000.

Authors:  Marion L Hartley; Najeebah A Bade; Petra A Prins; Leonel Ampie; John L Marshall
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Pancreatic cancer, treatment options, and GI-4000.

Authors:  Marion L Hartley; Najeebah A Bade; Petra A Prins; Leonel Ampie; John L Marshall
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 3.  Viroimmunotherapy for Colorectal Cancer: Clinical Studies.

Authors:  Shyambabu Chaurasiya; Susanne Warner
Journal:  Biomedicines       Date:  2017-03-10

Review 4.  Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy.

Authors:  Vinod Vijay Subhash; Mei Shi Yeo; Woei Loon Tan; Wei Peng Yong
Journal:  J Immunol Res       Date:  2015-10-22       Impact factor: 4.818

Review 5.  Vaccines in Gastrointestinal Malignancies: From Prevention to Treatment.

Authors:  Rani Chudasama; Quan Phung; Andrew Hsu; Khaldoun Almhanna
Journal:  Vaccines (Basel)       Date:  2021-06-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.